The 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension provide a comprehensive update on the management of pulmonary hypertension (PH), emphasizing a multidisciplinary approach. The guidelines, developed by a task force from the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), are endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Key updates include: - Revised haemodynamic definitions and classifications, including a new algorithm for earlier detection. - Expanded risk-stratification tables with additional echocardiographic and cardiac MRI prognostic indicators. - Simplified initial drug therapies based on a revised three-strata, multiparametric risk model. - Modified treatment algorithms for chronic thrombo-embolic pulmonary hypertension (CTEPH) and chronic thrombo-embolic pulmonary disease (CTEPD) without PH. - Introduction of new standards for PH centres and active involvement of patient representatives. The guidelines cover all types of PH, with a focus on pulmonary arterial hypertension (PAH) and CTEPH. They provide detailed recommendations for diagnosis, risk assessment, and treatment, including specific guidelines for different subgroups of PH. The guidelines also address the role of off-label medication use and ethical considerations in clinical practice. Overall, the 2022 ESC/ERS Guidelines aim to enhance the clinical management of PH by providing clear, evidence-based recommendations to healthcare professionals.The 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension provide a comprehensive update on the management of pulmonary hypertension (PH), emphasizing a multidisciplinary approach. The guidelines, developed by a task force from the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), are endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Key updates include: - Revised haemodynamic definitions and classifications, including a new algorithm for earlier detection. - Expanded risk-stratification tables with additional echocardiographic and cardiac MRI prognostic indicators. - Simplified initial drug therapies based on a revised three-strata, multiparametric risk model. - Modified treatment algorithms for chronic thrombo-embolic pulmonary hypertension (CTEPH) and chronic thrombo-embolic pulmonary disease (CTEPD) without PH. - Introduction of new standards for PH centres and active involvement of patient representatives. The guidelines cover all types of PH, with a focus on pulmonary arterial hypertension (PAH) and CTEPH. They provide detailed recommendations for diagnosis, risk assessment, and treatment, including specific guidelines for different subgroups of PH. The guidelines also address the role of off-label medication use and ethical considerations in clinical practice. Overall, the 2022 ESC/ERS Guidelines aim to enhance the clinical management of PH by providing clear, evidence-based recommendations to healthcare professionals.